Rosiglitazone monotherapy in mild-to-moderate alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study

Dementia and Geriatric Cognitive Disorders

Volumn 30, Issue 2, 2010, Pages 131-146

  Gold, Michael ^a   Alderton, Claire ^a   Zvartau Hind, Marina ^a   Egginton, Sally ^b   Saunders, Ann M ^c   Irizarry, Michael ^a   Craft, Suzanne ^d   Landreth, Gary ^e   Linnamägi, Ülla ^f   Sawchak, Sharon ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TARTU   (Estonia)

Author keywords

Alzheimer's disease; ApolipoproteinE allele 4; Cognition; Donepezil; Health outcomes; Monotherapy; Peroxisome proliferator activated receptor ; Rosiglitazone, extended release

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL; PLACEBO; ROSIGLITAZONE;

ADULT; AGED; ALZHEIMER DISEASE; ANEMIA; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FRACTURE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEADACHE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; INSOMNIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEOPLASM; OPEN STUDY; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; DRUG TOXICITY; EDEMA; FEMALE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; INDANS; INTELLIGENCE TESTS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; NASOPHARYNGITIS; PIPERIDINES; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77956090575     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318845     Document Type: Article

References (60)

1. Cummings JL: Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
2. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17: 27-45.
3. Craft S: Insulin resistance and Alzheimer' disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007; 4: 147-152.
4. Craft S: The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009; 66: 300-305.
5. Profenno LA, Porsteinsson AP, Faraone SV: Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67: 505-512.
6. Solfrizzi V, Scafato E, Capurso C, et al: Metabolic syndrome, mild cognitive impairment, and progression to dementia: the Italian Longitudinal Study on Aging. Neurobiol Aging 2009, E-pub ahead of print.
7. Forti P, Pisacane N, Rietti E, et al: Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 2010; 58: 487-492.
8. Geroldi C, Frisoni GB, Paolisso G, et al: Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005; 62: 1067-1072.
9. Bourdel-Marchasson I, Lapre E, Laksir H, Puget E: Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 2010; 36: 173-181.
10. Rasgon NL, Kenna HA, Wroolie TE, et al: Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2009, E-pub ahead of print.
11. de Felice FG, Vieira MN, Bomfim TR, et al: Protection of synapses against Alzheimer'slinked toxins: insulin signaling prevents the pathogenic binding of A oligomers. Proc Natl Acad Sci USA 2009; 106: 1971-1976.
12. Park CR, Seeley RJ, Craft S, Woods SC: Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000; 68: 509-514.
13. Craft S, Asthana S, Cook DG, et al: Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28: 809-822.
14. Reger MA, Watson GS, Green PS, et al: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440-448.
15. Balfour JA, Plosker GL: Rosiglitazone. Drugs 1999; 57: 921-930.
16. Strum JC, Shehee R, Virley D, et al: Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007; 11: 45-51.
17. Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28: 551-558.
18. Ghisletti S, Huang W, Ogawa S, et al: Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPAR. Mol Cell 2007; 25: 57-70.
19. Nicolakakis N, Aboulkassim T, Ongali B, et al: Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor-agonist. J Neurosci 2008; 28: 9287-9296.
20. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199: 265-273.
21. Toledo EM, Inestrosa NC: Activation of Wn signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/ PSEN1 E9 mouse model of Alzheimer's disease. Mol Psychiatry 2010; 15: 272-285, 228.
22. Watson GS, Cholerton BA, Reger MA, et al: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958.
23. Risner ME, Saunders AM, Altman JF, et al: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-254.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
25. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
26. Román GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260.
27. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
28. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32.
29. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
30. Gélinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-481.
31. Glaxo Smith Kline: AVANDIA prescribing information. Research Triangle Park, Glaxo-SmithKline.
32. Doward LC: The development of the Alzheimer's Carers' Quality of Life Instrument (ACQLI). Qual Life Res 1997; 6: 639.
33. Wimo A, Wetterholm AL, Mastey V, Winblad B: Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials: a quantitative battery; in Wimo A, Karlsson G, Jonsson B, Winblad B (eds): The Health Economics of Dementia. London, John Wiley & Sons, 1998, pp 465-499.
34. EuroQol Group: EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
35. Lane P: Handling dropout in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008; 7: 93-106.
36. Gold M: Study design factors and patient de-mographics and their effect on the decline of placebo-treated subjects in randomized clin-ical trials in Alzheimer's disease. J Clin Psy-chiatry 2007; 68: 430-438.
37. Kreider M, Heise M: Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Int J Clin Pract 2002; 56: 538-541.
38. Rogers SL, Farlow MR, Doody RS, Mohs R Friedhoff LT: A 24-week, double-blind, pla-cebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
39. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease: re-sults from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
40. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J: A 52-week study of the efficacy of rivastigmine in patients with mild to moder-ately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-241.
41. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54:2261-2268.
42. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: mul-ticentre randomised controlled trial. Galan-tamine International-1 Study Group. BMJ 2000; 321:1445-1449.
43. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS: Individual growth curve analysis of APOE?4-associated cogni-tive decline in Alzheimer disease. Arch Neu-rol 2005; 62: 454-459.
44. Frisoni GB, Govoni S, Geroldi C, et al: Gene dose of the?4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995; 37: 596-604.
45. Stern Y, Brandt J, Albert M, et al: The absence of an apolipoprotein?4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41:615-620.
46. Irizarry MC, Webb DJ, Bains C, et al: Predic-tors of placebo group decline in the Alzhei-mer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24-week clinical trials of Alzheimer's disease. J Alzheimers Dis 2008; 14: 301-311.
47. Doraiswamy PM, Krishnan KR, Anand R, et al: Long-term effects of rivastigmine in mod-erately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychia-try 2002; 26: 705-712.
48. Kurz A, Farlow M, Quarg P, Spiegel R: Dis-ease stage in Alzheimer disease and treat-ment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004; 18: 123-128.
49. Maher-Edwards G, Zvartau-Hind M, Hunt-er AJ, et al: Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res 2009, E-pub ahead of print.
50. Cukierman-Yaffee T: The relationship be-tween dysglycemia and cognitive dysfunc-tion. Curr Opin Investig Drugs 2009; 10:70-74.
51. Craft S, Dagogo-Jack SE, Wiethop BV, et al: Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 1993; 107:926-940.
52. Domínguez RO, Marschoff ER, Guareschi EM, et al: Insulin, glucose and glycated he-moglobin in Alzheimer's and vascular de-mentia with and without superimposed type II diabetes mellitus condition. J Neural Transm 2008; 115:77-84.
53. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specif-ic deletion of peroxisome proliferator-acti-vated receptor-7 blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102:9406-9411.
54. Yang T, Soodvilai S: Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008; 2008:943614.
55. Karalliedde J, Buckingham RE: Thiazolidin-ediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007; 30:741-753.
56. Cortes F, Nourhashémi F, Guérin O, et al: Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers De-ment 2008; 4:22-29.
57. Schneider LS, Sano M: Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009; 5:388-397.
58. Gendelman HE: Biomarkers, laboratory, and animal models for the design and develop-ment of adjunctive therapies for HIV-1 de-mentia and other neuroinflammatory disor-ders. J Neuroimmune Pharmacol 2007; 2: 8-13.
59. Bauer B, Hartz AM, Miller DS: Tumor necro-sis factor-α and endothelin-1 increase P-gly-coprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007; 71: 667-675.
60. Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, Pan W: Neuroinflammation ac-tivates Mdr1b efflux transport through NF-κB: promoter analysis in BBB endothelia. Cell Physiol Biochem 2008; 22:745-756.